

ESMO ADVANCED COURSE PROGRAMME

PARP INHIBITION: THERAPEUTIC APPLICATIONS IN ONCOLOGY

A shared and organ specific view on different cancer locations

Barcelona, Spain
29-30 October 2024

CO-CHAIRS

Elena Castro, Spain
Isabelle Ray-Coquard, France

SPEAKERS

Talia Golan, Israel
Olivia Le Saux, France
Christopher Lord, United Kingdom
Iain McNeish, United Kingdom
Natacha Naoun, France
Koen Van De Vijver, Belgium

LEARNING OBJECTIVES

- To get an overview on transversal thematic for dedicated pathway to improve competencies
- To understand the mechanism of resistance
- To share knowledge by experts from organ specific experiences
- To understand the basics of DNA repair machinery and the role of PARP
- To learn about the development of PARP inhibition in cancer treatment
- To cross compare clinical experience and safety of PARPi in different tumour types
- To learn about experiences from each other to improve knowledge in the field of PARPi use and development
- To identify the challenges of PARP inhibition: overcoming PARPi resistance and future research

Tuesday, 29 October 2024

09:00-09:10 **Welcome and opening**

10' Welcome and opening
Elena Castro, ES and Isabelle Ray-Coquard, FR

09:10-11:05 **Session 1 – Introduction** **Chair: Isabelle Ray-Coquard, FR**

40' Defects in DNA repair mechanisms across tumour types
Natacha Naoun, FR

20' Targeting DNA repair pathway and PARPi MOA (catalytic versus trapping activity...)
Christopher Lord, UK

20' Molecular biomarkers predicting PARPi efficacy (GIS, and beyond)
Olivia Le Saux, FR

20' Primary versus secondary resistance to PARPi: Incidence across tumour types, mechanisms, etc.
Iain McNeish, UK

15' Discussion

11:05-11:35 Coffee break

11:35-13:30 **Session 2 – Recent advances in PARP inhibition results in approved indications and other models**

Chair: Elena Castro, ES

20' Ovarian cancer
Isabelle Ray-Coquard, FR

20' Breast cancer
TBC

20' Prostate cancer
Elena Castro, ES

20' Pancreatic cancer
Talia Golan, IL

20' Other models
Natacha Naoun, FR

15' Discussion

13:30-14:30 Lunch

- 14:30-16:05** **Session 3 – Comparing efficacy of PARP inhibition across tumour types**
Chair: Isabelle Ray-Coquard, FR
- 20' Shared experience of PARPi in the metastatic setting (w/ maintenance): Prostate/ovary example of rucaparib
Elena Castro, ES and Iain McNeish, UK
- 20' Rationale and development of PARPi adjuvant versus advanced or relapse: Ovary/breast example of olaparib
Isabelle Ray-Coquard, FR
- 20' What we learn from Phase I with PARPi (including PKPD, translational in parallel, biomarkers...)
TBC
- 20' Biomarker selection (BRCA, tumour agnostic, ctDNA)
Olivia Le Saux, FR
- 15' Discussion
- 16:05-16:35** *Coffee break*
- 16:35-17:30** **Session 4 – Clinical practices in routine**
Chair: Elena Castro, ES
- 15' Current medical practices with PARPi in ESMO guidelines
Olivia Le Saux, FR
- 15' Testing optimization in clinical practice
Koen Van De Vijver, BE
- 15' Toxicity management cross vision (focus point on hematologic toxicity)
TBC
- 10' Discussion
- 17:30-18:25** **Session 5 – Future directions of PARP inhibition**
Chair: Isabelle Ray-Coquard, FR
- 15' Future directions (new molecules, new indications) – notes: Prevention, early stage
Christopher Lord, UK
- 30' New designs and new combinations exploring the benefit of PARPi
TBC
- 10' Discussion
- 20:00** *Networking dinner*

Wednesday, 30 October 2024

09:00-12:30

Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)

15' Introduction based on clinical cases presented by speakers

40' Discussion

5' Break

Workshop 1

60'

Clinical case Prostate cancer including Parpi therapy
Elena Castro, ES

Workshop 2

60'

Clinical case Breast cancer including Parpi therapy
TBC

11:00-11:30

Coffee break

Workshop 3

60'

Clinical case Ovarian cancer including Parpi therapy
Isabelle Ray-Coquard, FR

12:30-12:45

Feedback on the workshops from each group

Natacha Naoun, FR

12:45-13:00

Synthesis and wrap-up

Elena Castro, ES and Isabelle Ray-Coquard, FR

13:00-14:00

Lunch